XML 52 R40.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Collaboration Agreements, License Agreement and Revenues - Drug Product Revenue - Summary of Drug Product Revenue (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2024
Jun. 30, 2023
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Drug product revenue recognized $ 50,641 $ 44,319   $ 106,544 $ 80,480
Drug Product Revenue, Net [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Drug product revenue recognized 729 14,272   25,216 16,381
Drug Product Revenue, Net [Member] | Japan [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Drug product revenue recognized   14,400 $ 1,700    
Drug Product Revenue, Net [Member] | Astellas Agreement [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Drug product revenue recognized 700     500  
Drug Product Revenue, Net [Member] | Astellas Agreement [Member] | Japan [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Drug product revenue recognized (366) 13,809   (2,571) 15,541
Drug Product Revenue, Net [Member] | Astellas Agreement [Member] | Europe [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Drug product revenue recognized 1,095 463   2,116 840
Drug Product Revenue, Net [Member] | AstraZeneca Agreements [Member] | U.S. [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Drug product revenue recognized $ 0 $ 0   $ 25,671 $ 0